-
公开(公告)号:US20240355417A1
公开(公告)日:2024-10-24
申请号:US18618412
申请日:2024-03-27
Applicant: BioNTech SE , InstaDeep Ltd
Inventor: Alexander Muik , Ugur Sahin , Asaf Poran , Alexandra Walls , Yunguan Fu , Rafal Okuniewski , Nicolas Winfried Pfeuffer
Abstract: The present disclosure, among other things, provides technologies for identifying, characterizing, and/or monitoring variant sequences of a particular reference infections agent. Among other things, systems, methods, and architectures described herein provide visualization and decision support tools that can, e.g., facilitate decision making processes by local authorities and improve pandemic response in terms of, e.g., resource allocation, policy making, and speed tailored vaccine development. The present disclosure also provides tools for analyzing circulating variants to predict mutations likely to increase immune evasion of infectious agents.
-
公开(公告)号:US20240321387A1
公开(公告)日:2024-09-26
申请号:US18289424
申请日:2022-05-04
Applicant: BioNTech SE , InstaDeep Ltd
Inventor: Alexander Muik , Asaf Poran , Yunpeng Liu , Ugur Sahin , Karim Beguir , Marcin Skwark , Thomas Pierrot , Yunguan Fu
Abstract: A method is provided for identifying a number of variants of concern of a reference disease associated immunogen. The method uses a language model to perform inference on data representing each of a plurality of variants and data representing the reference immunogen. For each of the plurality of variants and the reference immunogen, a characteristic vector is derived from an output feature map of a hidden layer of the language model. For each of the plurality of variants, a measure of distance is generated for the variant that includes calculating a measure of distance between the characteristic vector of the variant and the characteristic vector of the reference immunogen. A semantic change score is calculated for each variant based on the generated measure of distance for that variant. A variant of the reference immunogen is selected based, at least in part, on the generated the semantic change scores.
-
公开(公告)号:US20240339174A1
公开(公告)日:2024-10-10
申请号:US18289425
申请日:2022-05-04
Applicant: BioNTech SE , InstaDeep Ltd.
Inventor: Alexander Muik , Asaf Poran , Yunpeng Liu , Ugur Sahin , Karim Beguir , Marcin Skwark , Thomas Pierrot , Yunguan Fu
IPC: G16B20/20 , C07K14/005 , G16B15/30 , G16B40/20
CPC classification number: G16B20/20 , C07K14/005 , G16B15/30 , G16B40/20 , C12N2770/20022
Abstract: The present disclosure provides technologies for identifying, characterizing, and/or monitoring sequences of a variant of a reference infectious agent (e.g., but not limited to viral variants, for example in some embodiments SARS-CoV-2 variants) for transmissibility factors and/or immune escape potential, and/or for detecting and/or monitoring variants in environmental or biological samples, and/or for designing, preparing, and/or administering vaccines for such variants.
-
公开(公告)号:US20230338512A1
公开(公告)日:2023-10-26
申请号:US18071499
申请日:2022-11-29
Applicant: BioNTech SE
Inventor: Alexander Muik , Asaf Poran , Kena Anne Swanson , Qi Yang , Hui Cai
IPC: A61K39/215 , A61K45/06
CPC classification number: A61K39/215 , A61K45/06 , A61K2039/53
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号:US20240366754A1
公开(公告)日:2024-11-07
申请号:US18701119
申请日:2022-10-14
Applicant: BioNTech SE
Inventor: Richard B. Gaynor , Michael Steven Rooney , Asaf Poran , Theresa Addona , Scott Goulding , Ekaterina Esaulova , Miles Kirsch , Yunpeng Liu , Lauren Stopfer
IPC: A61K39/25 , A61K39/00 , A61K39/12 , A61K39/245 , A61P37/04 , C07K14/005
Abstract: The present disclosure provides pharmaceutical compositions for delivery of viral antigens (e.g., a viral vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).
-
公开(公告)号:US20240000921A1
公开(公告)日:2024-01-04
申请号:US18341590
申请日:2023-06-26
Applicant: BioNTech SE
Inventor: Alexander Muik , Asaf Poran , Kena Anne Swanson , Qi Yang , Hui Cai , Ugur Sahin , Kayvon Modjarrad
IPC: A61K39/215 , C07K14/005
CPC classification number: A61K39/215 , A61K2039/53 , C07K14/005
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
-
公开(公告)号:US12186387B2
公开(公告)日:2025-01-07
申请号:US18071499
申请日:2022-11-29
Applicant: BioNTech SE
Inventor: Alexander Muik , Asaf Poran , Kena Anne Swanson , Qi Yang , Hui Cai , Ugur Sahin
IPC: A61K39/215 , A61K9/127 , A61K39/145 , A61K45/06 , A61K47/26 , C12N15/86 , A61K39/00
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号:US20240042011A1
公开(公告)日:2024-02-08
申请号:US18186914
申请日:2023-03-20
Applicant: BioNTech SE
Inventor: Alexander Muik , Asaf Poran , Kena Anne Swanson , Qi Yang , Hui Cai , Ugur Sahin
IPC: A61K39/215 , A61K39/145 , A61K9/127 , A61K47/26 , C12N15/86
CPC classification number: A61K39/215 , A61K39/145 , A61K2039/545 , A61K47/26 , C12N15/86 , A61K9/1272
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号:US20240366751A1
公开(公告)日:2024-11-07
申请号:US18526938
申请日:2023-12-01
Applicant: BioNTech SE
Inventor: Alexander Muik , Asaf Poran , Kena Anne Swanson , Qi Yang , Hui Cai , Ugur Sahin , Kayvon Modjarrad
IPC: A61K39/215 , A61K39/00 , C07K14/005
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
-
公开(公告)号:US20230201817A1
公开(公告)日:2023-06-29
申请号:US18085206
申请日:2022-12-20
Applicant: BioNTech Delivery Technologies GmbH , BioNTech SE
Inventor: Christian Reinsch , David Estapé Izquierdo , Sierk Poetting , Ugur Sahin , Alexander Muik , Asaf Poran , Martin Lang , Oliver Hennig , Karsten Pietron-Kattmann , Manfred Brunen , Rainer Kröner , Mario Büttner , Sven Stegmann , Kristin Hoffmann
CPC classification number: B01L1/52 , A61K39/215 , B01D61/145 , B01D61/147 , B01D61/149 , B01F25/25 , G16B20/20 , G16B30/00 , G16B50/30 , A61K2039/53
Abstract: A portable system for producing a formulation comprising lipid nanoparticle (LNP)-encapsulated RNA includes: a first sub-system comprising multiple drug substance formulation modules, the first sub-system comprising: a transcription module for forming an RNA solution via in vitro transcription; and a second sub-system operatively downstream of the first sub-system comprising multiple drug product formation modules, the second sub-system comprising: an LNP formulation module for producing a first RNA-LNP preparation from the RNA solution, wherein each of the transcription module and the LNP formulation module is contained within a separate standard shipping container.
-
-
-
-
-
-
-
-
-